Boston Therapeutics is a
pharmaceutical company focused on the development, manufacturing, and
commercialization of novel compounds based on complex carbohydrate chemistry to
address unmet medical needs in diabetes.
PAZ320 is an integral part
of the company’s initial product pipeline, which is focused on developing and
commercializing therapeutic molecules. PAZ320 is a non-systemic, non-toxic,
chewable drug which inhibits the enzymes that release glucose from complex
carbohydrates in foods during digestion, reducing the amount of available
glucose absorbed through the intestine.
In November, Boston
Therapeutics enrolled 24 patients with Type 2 diabetes in a Phase IIb clinical
study on PAZ320, and positive results from the trial were published by the
principal investigator in the July/August issue of the journal “Endocrine
Practice”. After evaluating the safety and efficacy of PAZ320, it was shown
that there was a significant 40% reduction in elevation of post-meal blood
glucose in the participating patients, with no serious adverse events.
By the second or third
quarter of 2014, the company hopes to begin an important Phase III trial of the
chewable tablet it is promoting as a potential adjunct to metformin in patients
living with Type 2 diabetes. While the Phase IIb trial was held only in France,
the Phase III trial will be multi-national–in the United States, Europe, Hong
Kong, and China.
The company believes that
PAZ320 is a safe and effective drug compound for people with pre-diabetes and
diabetes in their daily management of blood glucose levels, fulfilling an unmet
medical need. The intent is for this compound to provide individuals with a
means by which to slow the onset of Type 2 diabetes and/or the onset of
diabetes complications such as heart disease, stroke, kidney damage,
retinopathy, and Diabetic Foot.
PAZ320 is meant to be taken
before meals and works in the gastrointestinal tract to block the action of
carbohydrate-hydrolyzing enzymes that break down complex carbohydrates into
simple sugars, reducing the availability of glucose for absorption into the
bloodstream.
For more information about
PAZ320 or any of the company’s other products, visit the website at
www.bostonti.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
